top of page


Oxalo Therapeutics is a committed to developing first-in-class therapeutics to treat and prevent diseases caused by hyperoxaluria and hyperoxalemia. We are a preclinical stage biopharmaceutical company that leverages our expertise in the microbiome, translational research, and early stage technology commercialization to derive innovative therapies.


The needs of our patients and best-in-class research are the catalysts that drive our company. Based on breakthrough discoveries from gut microbes, Oxalo's approach mimics a natural mechanism to remove oxalate safely from the body and consequently prevent recurrent kidney stones and other oxalate pathologies.

Hatim Hassan

Hatim Hassan, MD, PhD is a co-founder and leads the research and development of Oxalo Therapeutics. Dr. Hassan is an Assistant Professor of Medicine at the University of Chicago and board certified in Internal Medicine and Nephrology. He has over 15 years of experience at the forefront of oxalate metabolism and kidney stones research. Specifically, Dr. Hassan is a world-renowned expert on the regulation of intestinal oxalate transport by neurohumoral factors and Oxalobacter formigenes (Of), and its pertinence to the risk of hyperoxaluria, hyperoxalemia, and related calcium oxalate kidney stones. He obtained his M.D. degree from the University of Khartoum Medical School in Sudan and his Ph.D. from the Yale University Investigative Medicine Program.

Yang Zheng

Yang Zheng is a co-founder and heads all business efforts of Oxalo Therapeutics. Prior to Oxalo, Mr. Zheng served as the VP of Operations for Seurat Therapeutics (another University of Chicago-spun biotechnology company) as well as the Director of Strategy and Operations for Clarix Imaging, helping the company raise over $2M in non-dilutive government funding. He also worked closely with the Polsky Center of Entrepreneurship and Innovation at UChicago as a Technology Venture Fellow to commercialize STEM research. Mr. Zheng received his B.A. in Business Economics from UCLA and is completing his M.B.A. from the University of Chicago Booth School of Business.

Leadership Team


At Oxalo, we are committed to developing innovative therapies for patients with severe and rare kidney diseases caused by oxalate.
Oxalo Therapeutics, Inc.
Polsky Exchange
1452 E. 53rd St, 2nd Floor
Chicago, IL 60615
bottom of page